INCY vs. TEM: Incyte vs. Tempus AI Stock Comparison

Company Profile

Incyte (INCY) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Incyte (INCY) carries decades of public-market history since November 4, 1993, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the INCY side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Incyte (INCY) is closer to market-like at 0.78 — a noticeable difference in market-sensitivity profile.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Incyte (INCY) reports 7.84%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Incyte (INCY) reports 6.71%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Incyte (INCY) reports 33.72%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Incyte (INCY) at 21.22% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: Incyte (INCY) reports EPS growth of 4,173.33%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Incyte (INCY) at 3.84 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Tempus AI (TEM) at 2.86 is above its industry debt-to-equity ratio range.

Financial Strength Metrics

Dividends

Neither Incyte (INCY) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Incyte (INCY) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Incyte (INCY) trades at 61.05 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

On P/S ratio, both Incyte (INCY) at 4.06 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Incyte (INCY) at 4.33 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

Valuation Metrics